In the phase III FLAURA trial, which compared osimertinib to first-generation EGFR-TKIs in advanced EGFR-mutant NSCLC, objective response rates (ORRs) were similar, but progression-free survival (PFS) and overall survival (OS) were significantly longer (18.9 vs 10.2 and 38.6 vs 31.8 months, respectively) (6, 7). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.